We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.53B
AUM Growth
+$17.2M
Cap. Flow
+$30.8M
Cap. Flow %
1.22%
Top 10 Hldgs %
72.66%
Holding
32
New
3
Increased
6
Reduced
2
Closed
2
Avg Time Held
7.5 quarters
Top 10 Avg Time Held
9.4 quarters
Top 20 Avg Time Held
8.6 quarters

Top Buys

Rank Stock Value
1
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$25.2M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$20.6M
3
MGNX icon
MacroGenics
MGNX
+$11.7M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$10.5M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$10M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$33.5M
2
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$14.2M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$10.1M
4
TSRO
TESARO, Inc.
TSRO
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Miscellaneous 4.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ACHN
26
DELISTED
Achillion Pharmaceuticals
ACHN
$9.98M 0.39%
1,279,340
– –
2013 Q2
12 quarters
ESPR icon
27
DELISTED
Esperion Therapeutics
ESPR
$9.96M 0.39%
1,008,542
– –
2015 Q3
3 quarters
PTCT icon
28
PTC Therapeutics
PTCT
$5.29B
$8.3M 0.33%
1,182,912
– –
2014 Q4
6 quarters
CDTX icon
29
DELISTED
Cidara Therapeutics
CDTX
$7.7M 0.3%
37,341
– –
2015 Q4
2 quarters
TBRA
30
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$5.88M 0.23%
+468,000
New +$4.36M
2016 Q2
0 quarters
INFI
31
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-2,700,737
Closed -$14.2M –
CLVS
32
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-528,188
Closed -$10.1M –
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2016 Portfolio in Review

As of Q2 2016, BB Biotech held 32 positions worth $2.53B, up 0.68% from $2.52B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BB Biotech's Q2 2016 filing shows 3 new, 6 increased, 2 reduced and 2 closed positions. Its largest new stake was Intra-Cellular Therapies Inc.: 700,000 shares worth $27.2M. The largest sale was MEDIVATION, INC., an estimated $33.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

  • BB Biotech's largest Q2 2016 buy was Intra-Cellular Therapies Inc.: 700,000 shares worth $27.2M.
  • BB Biotech added most to Alexion Pharmaceuticals in Q2 2016, an estimated $20.6M increase.
  • BB Biotech's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $33.5M.
  • BB Biotech fully exited Infinity Pharmaceuticals, Inc. in Q2 2016, selling an estimated $14.2M.
  • BB Biotech's ten largest holdings make up 73% of its $2.53B portfolio in Q2 2016.
  • BB Biotech opened 3 new positions and closed 2 in Q2 2016.
  • BB Biotech's portfolio value rose 0.68% quarter-over-quarter to $2.53B.

Based on BB Biotech's 13F filing for Q2 2016, filed 12 Aug 2016.